Fertility and Sterility
Volume 94, Issue 1 , Pages 211-215 , June 2010

Increased secretion of amylin in women with polycystic ovary syndrome

Presented in part at the Annual Meeting of the Society for Gynecologic Investigation, March 14–17, 2007, Reno, Nevada.

  • Summer James, M.D.
    • ,
  • Jennifer Moralez, M.D.
    • ,
  • Manubai Nagamani, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests: Manubai Nagamani, M.D., Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555-0587 (FAX: 281-486-5554).

Received 29 October 2008 ,Revised 25 February 2009 ,Accepted 25 February 2009.

References 

  1. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233–246
  2. Wookey PJ, Lutz TA, Andrikopoulos S. Amylin in the periphery II: an updated mini-review. Scientific World J. 2006;6:1642–1655
  3. Cooper GJ, Leighton B, Dimmitriadis GD, Parrybillings M, Kowalchuck JM, Howland K, et al. Amylin found in amyloid deposits in human type 2 diabetes may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci U S A. 1988;85:7763–7766
  4. Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake and obesity. Obes Res. 2002;10:1087–1091
  5. Rink TJ, Beaumont K, Koda J, Young A. Structure and biology of amylin. Trends Pharmacol Sci. 1993;14:113–118
  6. Butler AE, Janson J, Bonner-Weis S, Ritzel RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110
  7. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 1994;368:756–760
  8. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84:1897–1899
  9. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861
  10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169
  11. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens JR,  Haseltine F editor. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992;p. 377–384
  12. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol. 1961;21:1440–1447
  13. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol. 2006;91:4237–4245
  14. Reinehr T, de Sousa G, Niklowitz P, Roth Cl. Amylin and its relation to insulin and lipids in obese children before and after weight loss. Obesity. 2007;15:2006–2011
  15. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes. 1991;40:1615–1619
  16. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25:389–397
  17. Gedulin B, Cooper GJS, Young AA. Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin resistant diabetic rats. Biochem Biophys Res Comm. 1991;180:782–789
  18. Clodi M, Thomaseth K, Pacini G, Hermann K, Kautzky-Willer A, Waldhüsl W, et al. Distribution and kinetics of amylin in humans. Am J Physiol. 1998;274:E903–E908
  19. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647–654
  20. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139–146
  21. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med. 2008;358:47–54
  22. Leclerc I, Woltersdorf WW, da Silva Xavier G, Rowe RL, Cross SE, Korbutt GS, et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab. 2004;286:E1023–E1031
  23. Hull RL, Shen ZP, Watts MR, Kodama K, Carr DB, Utzschneider KM, et al. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes. 2005;54:2235–2244
  24. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3629–3643
  25. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA, et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes. 2007;56:2016–2027
  26. Khan KA, Stas S, Kurukulasuriya LA. Polycystic ovarian syndrome. J Cardiometab Syndr. 2006;1:125–130
  27. Diamanti-Kandarakis E, Papavassiliou AC, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007;18:280–285
  28. Smith D, Mamo JC. Islet amyloid polypeptide (amylin) modulates chylomicron metabolism in rats. Clin Exp Pharmacol Physiol. 2000;27:345–351
  29. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens. 2000;18:1611–1620
  30. Wookey PJ, Cao Z, Cooper ME. Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension. Miner Electrolyte Metab. 1998;24:389–399
  31. Cascella T, Palomba S, Tauchmanovà L, Manguso F, Di Biase S, Labella D, et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2006;91:4395–4400
  32. Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthews SL, et al. Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol. 1994;46:246–255
  33. Abe K, Minegishi T, Ibuki Y, Kojima M, Kangawa K. Expression of adrenomedullin in the human corpus luteum. Fertil Steril. 2000;74:141–145

 S.J. has nothing to disclose. J.M. has nothing to disclose. M.N. has nothing to disclose.

PII: S0015-0282(09)00513-5

doi: 10.1016/j.fertnstert.2009.02.086

Fertility and Sterility
Volume 94, Issue 1 , Pages 211-215 , June 2010

Article Tools

* Image Usage & Resolution